Patient Support Services Contact Us
Image: Coherus Investors

Overview

Investors

A fully integrated biopharmaceutical company with a robust pipeline across multiple therapeutic areas.

Coherus is a commercial stage biopharmaceutical company with the mission to increase patient access to cost-effective medicines that can have a major impact on their lives and to deliver significant savings to the health care system.

In January 2021, Coherus in-licensed Junshi Biosciences’ toripalimab, an anti-PD-1 antibody, which will be a cornerstone of Coherus’ strategy to build a leading immuno-oncology franchise in the United States and Canada funded with cash generated by its commercial biosimilar business. Coherus markets UDENYCA® (pegfilgrastim-cbqv) in the United States and through 2023 expects to launch biosimilars of Humira®, Avastin® and Lucentis®, if approved.

Coherus is headquartered in the heart of California’s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.

News
06/04/21
– Virtual investor event to take place on Monday, June 7, 2021 at 6 p.m. ET – SHANGHAI, China , and REDWOOD CITY, Calif. , June 04, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co. , Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc.
06/03/21
– In pivotal Phase 3 JUPITER-02 study, toripalimab plus chemotherapy significantly improved PFS compared to chemotherapy alone in high and low PD-L1 expression subgroups – –  Although median overall survival (OS) analysis was not yet mature, a 40% reduction in risk of death was observed in the
05/07/21
REDWOOD CITY, Calif. , May 07, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming Bank of America Health Care Conference on Wednesday, May 12, 2021 at 1:15 p.m. EST / 10:15 a.m. PST .
05/06/21
– Junshi Biosciences transaction is followed by rapid toripalimab progress including initiation of first BLA submission to the U.S. FDA, positive interim analysis in pivotal esophageal cancer trial, and selection for ASCO plenary session – –Toripalimab is one of four additional Coherus product
Events & Presentations